Vermillion reported this week that its first-quarter revenues rose 5 percent to $328,000 from $312,000 in Q1 2012, beating the consensus Wall Street estimate of $300,000.

The company posted product revenue of $214,000, up 8 percent from $198,000 year over year. That revenue was based on 4,274 OVA1 ovarian cancer tests performed in Q1 versus 3,952 tests performed in the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.